Antibody-drug conjugates for cancer therapy

Chemistry to clinical implications

Nirnoy Dan, Saini Setua, Vivek K. Kashyap, Sheema Khan, Meena Jaggi, Murali Yallapu, Subhash Chauhan

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Chemotherapy is one of themajor therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatment. ADC technology uses an antibody-mediated delivery of cytotoxic drugs to the tumors in a targeted manner, while sparing normal cells. Such a targeted approach can improve the tumor-to-normal tissue selectivity and specificity in chemotherapy. Considering its importance in cancer treatment, we aim to review recent efforts for the design and development of ADCs. ADCs are mainly composed of an antibody, a cytotoxic payload, and a linker, which can offer selectivity against tumors, anti-cancer activity, and stability in systemic circulation. Therefore, we have reviewed recent updates and principal considerations behind ADC designs, which are not only based on the identification of target antigen, cytotoxic drug, and linker, but also on the drug-linker chemistry and conjugation site at the antibody. Our review focuses on site-specific conjugation methods for producing homogenous ADCs with constant drug-antibody ratio (DAR) in order to tackle several drawbacks that exists in conventional conjugation methods.

Original languageEnglish (US)
Article number32
JournalPharmaceuticals
Volume11
Issue number2
DOIs
StatePublished - Jun 1 2018

Fingerprint

Antibodies
Pharmaceutical Preparations
Neoplasms
Therapeutics
Drug Therapy
Technology
Organ Specificity
Drug Design
Antigens

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Antibody-drug conjugates for cancer therapy : Chemistry to clinical implications. / Dan, Nirnoy; Setua, Saini; Kashyap, Vivek K.; Khan, Sheema; Jaggi, Meena; Yallapu, Murali; Chauhan, Subhash.

In: Pharmaceuticals, Vol. 11, No. 2, 32, 01.06.2018.

Research output: Contribution to journalReview article

@article{40a323053abd44a4aad9082b65409284,
title = "Antibody-drug conjugates for cancer therapy: Chemistry to clinical implications",
abstract = "Chemotherapy is one of themajor therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatment. ADC technology uses an antibody-mediated delivery of cytotoxic drugs to the tumors in a targeted manner, while sparing normal cells. Such a targeted approach can improve the tumor-to-normal tissue selectivity and specificity in chemotherapy. Considering its importance in cancer treatment, we aim to review recent efforts for the design and development of ADCs. ADCs are mainly composed of an antibody, a cytotoxic payload, and a linker, which can offer selectivity against tumors, anti-cancer activity, and stability in systemic circulation. Therefore, we have reviewed recent updates and principal considerations behind ADC designs, which are not only based on the identification of target antigen, cytotoxic drug, and linker, but also on the drug-linker chemistry and conjugation site at the antibody. Our review focuses on site-specific conjugation methods for producing homogenous ADCs with constant drug-antibody ratio (DAR) in order to tackle several drawbacks that exists in conventional conjugation methods.",
author = "Nirnoy Dan and Saini Setua and Kashyap, {Vivek K.} and Sheema Khan and Meena Jaggi and Murali Yallapu and Subhash Chauhan",
year = "2018",
month = "6",
day = "1",
doi = "10.3390/ph11020032",
language = "English (US)",
volume = "11",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Antibody-drug conjugates for cancer therapy

T2 - Chemistry to clinical implications

AU - Dan, Nirnoy

AU - Setua, Saini

AU - Kashyap, Vivek K.

AU - Khan, Sheema

AU - Jaggi, Meena

AU - Yallapu, Murali

AU - Chauhan, Subhash

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Chemotherapy is one of themajor therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatment. ADC technology uses an antibody-mediated delivery of cytotoxic drugs to the tumors in a targeted manner, while sparing normal cells. Such a targeted approach can improve the tumor-to-normal tissue selectivity and specificity in chemotherapy. Considering its importance in cancer treatment, we aim to review recent efforts for the design and development of ADCs. ADCs are mainly composed of an antibody, a cytotoxic payload, and a linker, which can offer selectivity against tumors, anti-cancer activity, and stability in systemic circulation. Therefore, we have reviewed recent updates and principal considerations behind ADC designs, which are not only based on the identification of target antigen, cytotoxic drug, and linker, but also on the drug-linker chemistry and conjugation site at the antibody. Our review focuses on site-specific conjugation methods for producing homogenous ADCs with constant drug-antibody ratio (DAR) in order to tackle several drawbacks that exists in conventional conjugation methods.

AB - Chemotherapy is one of themajor therapeutic options for cancer treatment. Chemotherapy is often associated with a low therapeutic window due to its poor specificity towards tumor cells/tissues. Antibody-drug conjugate (ADC) technology may provide a potentially new therapeutic solution for cancer treatment. ADC technology uses an antibody-mediated delivery of cytotoxic drugs to the tumors in a targeted manner, while sparing normal cells. Such a targeted approach can improve the tumor-to-normal tissue selectivity and specificity in chemotherapy. Considering its importance in cancer treatment, we aim to review recent efforts for the design and development of ADCs. ADCs are mainly composed of an antibody, a cytotoxic payload, and a linker, which can offer selectivity against tumors, anti-cancer activity, and stability in systemic circulation. Therefore, we have reviewed recent updates and principal considerations behind ADC designs, which are not only based on the identification of target antigen, cytotoxic drug, and linker, but also on the drug-linker chemistry and conjugation site at the antibody. Our review focuses on site-specific conjugation methods for producing homogenous ADCs with constant drug-antibody ratio (DAR) in order to tackle several drawbacks that exists in conventional conjugation methods.

UR - http://www.scopus.com/inward/record.url?scp=85046164803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046164803&partnerID=8YFLogxK

U2 - 10.3390/ph11020032

DO - 10.3390/ph11020032

M3 - Review article

VL - 11

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 2

M1 - 32

ER -